Trial reportSchizophrenia bulletin2006
Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram.
Trial report in Schizophrenia bulletin, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review.Current neuropharmacology · 2024Pooled it
- Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Pooled it
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.Bipolar disorders · 2018Guideline
- The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists.The American journal of psychiatry · 2024Review
- Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.Innovations in clinical neuroscience · 2019Article
- Alcohol Use Disorder and Schizophrenia or Schizoaffective Disorder.Alcohol research : current reviews · 2019Review
- Medication-Assisted Treatment for Alcohol-Dependent Adults With Serious Mental Illness and Criminal Justice Involvement: Effects on Treatment Utilization and Outcomes.The American journal of psychiatry · 2018Article
- Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review.Therapeutic advances in psychopharmacology · 2017Review
- Disulfiram and Diphenhydramine Hydrochloride Upregulate miR-30a to Suppress IL-17-Associated Autoimmune Inflammation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2016Article
- Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.Drug safety · 2016Review
- Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders.Current addiction reports · 2014Article
- Substance abuse and schizophrenia: pharmacotherapeutic intervention.Journal of substance abuse treatment · 2008Review
- Endogenous opiates and behavior: 2006.Peptides · 2007Review
- Management of persons with co-occurring severe mental illness and substance use disorder: program implications.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2007Article
- Treatment of patients comorbid for addiction and other psychiatric disorders.Current psychiatry reports · 2007Review
- Enhancing validity in co-occurring disorders treatment research.Schizophrenia bulletin · 2006Review
- Concomitant medication of psychoses in a lifetime perspective.Human psychopharmacologyArticle
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rate of substance-use disorders in patients with mental illnesses within the psychotic spectrum, such as schizophrenia, schizoaffective disorder, and bipolar disorder, is higher than the rate observed in the general population and is associated with significant morbidity and mortality. Although there are currently 3 medications approved by the Food and Drug Administration for the treatment of alcohol dependence, no medications have been approved for the specific treatment of dually diagnosed patients. A small but growing body of literature supports the use of 2 of these medications, disulfiram and naltrexone, in dually diagnosed individuals. This article outlines a review of the literature about the use of disulfiram and naltrexone for alcoholism and in patients with comorbid mental illness. In addition, results are presented of a 12-week randomized clinical trial of disulfiram and naltrexone alone and in combination for individuals with Axis I disorders and alcohol dependence who were also receiving intensive psychosocial treatment. Individuals with a psychotic spectrum disorder, including schizophrenia, schizoaffective disorder, and bipolar disorder, had worse alcohol outcomes than those without a psychotic spectrum disorder. Individuals with a psychotic spectrum disorder had better alcohol-use outcomes on an active medication compared with placebo, but there was no clear advantage of disulfiram or naltrexone or of the combination. Retention rates and medication compliance in the study were high and exceeded 80%. Pharmacotherapeutic strategies should take into account the advantages and disadvantages of each medication. Future directions of pharmacotherapeutic options are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.